iPS Cells & Regenerative Medicine– category –
-
Ultragenyx’s Genglycos Secures FDA Approval as First Gene Therapy for GSDIa – Bolstering In-House Manufacturing and Long-Term Post-Marketing Monitoring
Pharmaceutical Technology USA Overview Ultragenyx Pharmaceutical has received FDA accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), the first gene therapy targeting the root cause of the ultra-rare metabolic disorder,... -
Ultragenyx’s Genglycos Receives FDA Accelerated Approval as First Gene Therapy for Glycogen Storage Disease Type Ia, Requiring 10-Year Post-Marketing Monitoring
Pharmaceutical Technology USA Overview Ultragenyx Pharmaceutical announced that Genglycos (pariglasgene brecaparvovec-opnr), the first gene therapy for Glycogen Storage Disease Type Ia (GSDIa), has received FDA accelerated approval. This... -
Moffitt Cancer Center’s Dr. Yvonne Chen Proposes Novel Strategies to Overcome Tumor Microenvironment Barriers in Solid Tumors with Logic-Gated CAR T-Cells
Moffitt Cancer Center USA Overview Dr. Yvonne Chen of Moffitt Cancer Center has discussed new strategies to enhance CAR-T cell therapy for solid tumors, focusing on precise targeting with logic-gated CAR-T cells and reprogramming the tum... -
2026 ‘In Vivo CRISPR Medicine’ Symposium to Focus on Commercialization and Scalable Deployment of In Vivo Genome Editing
CRISPR Medicine News (CMN x CSGCT Virtual Symposium) USA Overview The upcoming 'In Vivo CRISPR Medicine: From Scientific Promise to Patients at Scale' virtual symposium on September 3, 2026, will highlight the transition of in vivo genom... -
CRDWC 2026 Symposium to Address CAR-T Challenges in Solid Tumors: Focus on Design, Manufacturing, and Safety Strategies
CRDWC 2026 (Cancer Research and Development Conference 2026) Unknown Overview The 2026 Cancer Research and Development Conference will host a symposium dedicated to expanding CAR-T cell therapy from hematological malignancies to solid tu... -
Next-Generation Bioinks Create New Opportunities in Tissue Engineering and Drug Discovery via 3D Bioprinting
ACS Publications USA Overview Advances in next-generation bioinks are significantly propelling the fields of tissue engineering and regenerative medicine through 3D bioprinting technology. These bioinks are essential for creating microen... -
Penn State Team Establishes Foundation for 3D Bioprinted Spheroids to Promote Bone Tissue Regeneration and Vascularization
Penn State News USA Overview An interdisciplinary team at Penn State University has laid the groundwork for 3D printing spheroids, small living cell clusters, capable of regenerating bone tissue following severe trauma or infection. Rese... -
Chinese iPSC-Derived Cardiomyocyte Therapy Significantly Improves Heart Function in 90% of Heart Failure Patients in Landmark Phase 2 Trial, Published in Nature Medicine
South China Morning Post China Overview A groundbreaking Phase 2 clinical trial conducted by Nanjing Drum Tower Hospital in China reported that 90% of heart failure patients who received iPSC-derived cardiomyocyte injections showed signi... -
DelveInsight Report: Over 12 Companies Enter iPSC-Derived NK Cell Therapy Pipeline, Led by Century Therapeutics and Fate Therapeutics
openPR.com (DelveInsight) India Overview This article provides an overview of a market research report published by DelveInsight, highlighting the rapid growth in the iPSC-derived NK cell therapy pipeline, with over 12 companies developi... -
Allogene Therapeutics’ TALEN-Edited Lymphoma Cell Therapy cema-cel Receives FDA RMAT and Fast Track Designations, Achieves 58.3% MRD Negativity in Phase 2 Trial
PRISM MarketView USA Overview Allogene Therapeutics' TALEN-edited allogeneic cell therapy, cema-cel, has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA, accelerating its regulatory pa...
